We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators.
Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan.
With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development.
Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.
Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan.
With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development.
Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $380M
Founded date: 2014
Investors 3
Date | Name | Website |
- | Taihill Ve... | taihill.vc |
06.09.2022 | Skylight I... | skylightin... |
23.02.2022 | 5Y Capital | 5ycap.com |
Funding Rounds 3
Date | Series | Amount | Investors |
29.09.2020 | Series C | $319M | - |
29.10.2018 | Series B | $46M | - |
23.01.2018 | Series B | $15M | - |
Mentions in press and media 40
Date | Title | Description |
10.10.2024 | Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform | CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnso... |
30.09.2024 | Tiny Black Holes: The Cosmic Ghosts That Could Shake Mars | In the vast expanse of our universe, mysteries lurk like shadows. Among them are tiny black holes, ancient remnants from the dawn of time. These elusive entities may drift through our Solar System, stirring the orbits of planets like Mars. ... |
24.09.2024 | XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP | BOSTON and SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- Today, XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug discovery. Upon this launch, Xt... |
11.09.2024 | PhoreMost raises £33M to advance 'Drugging the Undruggable' research | PhoreMost, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, has completed an oversubscribed £33 million Series B investment round. PhoreMost’s SITESEEKER platform can identify the best new the... |
21.08.2024 | 51World‘s earth cloning tech secures backing from Chinese state-owned investor | Header image source: 51World. 51World, a Beijing-based digital twin technology company, has raised RMB 200 million (USD 28 million) in a pre-IPO funding round, according to 36Kr. This latest investment marks a significant milestone for the ... |
11.03.2024 | Artificial Intelligence in Healthcare Market Size, Share And Growth Analysis For 2024-2033 | Artificial Intelligence In Healthcare Global Market Report 2024 – Market Size, Trends, And Global Forecast 2023-2032 The Business Research Company's Artificial Intelligence In Healthcare Global Market Report 2024 – Market Size, Trends, And ... |
30.01.2024 | XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery | CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation... |
27.11.2023 | XtalPi and HKU's Advanced Biomedical Instrumentation Centre Sign MoU to Accelerate Deep Tech Commercialization | CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- XtalPi Inc. (XtalPi) and the Advanced Biomedical Instrumentation Centre (ABIC or the Centre) at the University of Hong Kong (HKU) have entered a memorandum of understanding (MoU) that outlines... |
31.05.2023 | XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics | XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Comp... |
30.05.2023 | Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal | Ma Jian, cofounder and CEO of Xtalpi.Xtalpi |
Show more